» Articles » PMID: 16280052

Patterns of Reduced Nipple Aspirate Fluid Production and Ductal Lavage Cellularity in Women at High Risk for Breast Cancer

Overview
Specialty Oncology
Date 2005 Nov 11
PMID 16280052
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Nipple aspiration is a noninvasive technique for obtaining breast fluids from the duct openings of the nipple for the evaluation of abnormalities associated with breast cancer. Nipple aspirate fluid (NAF) can be elicited from 48 to 94% of healthy women, and its production has been linked to an increased relative risk for breast cancer development. NAF production has been used in studies to guide the selection of ducts for ductal lavage, a procedure in which ducts are cannulated and flushed with saline to collect cells. In a previous multicenter trial to evaluate intraductal approaches in women at high-risk for breast cancer, NAF production was observed in 84% of the subjects. However, we observed a significantly lower proportion of fluid-yielding subjects in a similar series of high-risk women. The purpose of the present study was to identify variables associated with this reduction.

Method: Nipple aspiration was performed on 33 high-risk women (defined as having a 5-year Gail model index of more than 1.7, a personal or family history of breast cancer, and/or a BRCA1 or BRCA2 germline mutation) to identify ductal orifices for lavage procedures. Lavage was performed on all fluid-yielding ducts and on nine non-fluid-yielding ducts.

Results: Fluid-yielding ducts were identified in 12 of 33 (36%) of the subjects in the present series, compared with 16 of 19 (84%) of the subjects undergoing identical procedures at our facility during a multicenter trial (P = 0.001). Reduced NAF yields were associated with postmenopausal status (P = 0.02), BRCA germline mutations (P = 0.004), and risk reduction therapies, including bilateral salpingo-oophorectomy (BSO) and/or selective estrogen receptor modulators (SERMs; P = 0.009). All nine (100%) of the ductal lavage specimens collected from non-fluidyielding ducts were acellular, in comparison with 3 of 13 specimens from fluid-yielding ducts (P < .001).

Conclusion: Analysis of high-risk women in the present series revealed patterns of reduced NAF production and ductal lavage cellularity compared with a previous multicenter trial. The present series included more BRCA-positive women, many of whom had undergone BSO and/or were using SERMs. Our data suggest that endocrine mechanisms associated with these risk-reducing therapies may be related to patterns of diminished breast fluid production.

Citing Articles

Elemental bioimaging shows mercury and other toxic metals in normal breast tissue and in breast cancers.

Pamphlett R, Satgunaseelan L, Kum Jew S, Doble P, Bishop D PLoS One. 2020; 15(1):e0228226.

PMID: 32004334 PMC: 6993973. DOI: 10.1371/journal.pone.0228226.


An efficient biomarker panel for diagnosis of breast cancer using surface-enhanced laser desorption ionization time-of-flight mass spectrometry.

Yigitbasi T, Calibasi-Kocal G, Buyukuslu N, Atahan M, Kupeli H, Yigit S Biomed Rep. 2018; 8(3):269-274.

PMID: 29456844 PMC: 5795628. DOI: 10.3892/br.2018.1042.


Repeated nipple fluid aspiration: compliance and feasibility results from a prospective multicenter study.

de Groot J, Moelans C, Elias S, Hennink A, Verolme B, Suijkerbuijk K PLoS One. 2015; 10(5):e0127895.

PMID: 26000714 PMC: 4441497. DOI: 10.1371/journal.pone.0127895.


Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer.

Chung L, Moore K, Phillips L, Boyle F, Marsh D, Baxter R Breast Cancer Res. 2014; 16(3):R63.

PMID: 24935269 PMC: 4095593. DOI: 10.1186/bcr3676.


Metabolomic characterization of nipple aspirate fluid by (1)H NMR spectroscopy and GC-MS.

Tredwell G, Miller J, Chow H, Thompson P, Keun H J Proteome Res. 2013; 13(2):883-9.

PMID: 24364541 PMC: 4423791. DOI: 10.1021/pr400924k.


References
1.
Narod S, Brunet J, Ghadirian P, Robson M, Heimdal K, Neuhausen S . Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 2000; 356(9245):1876-81. DOI: 10.1016/s0140-6736(00)03258-x. View

2.
Cauley J, Norton L, Lippman M, Eckert S, Krueger K, Purdie D . Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. 2001; 65(2):125-34. DOI: 10.1023/a:1006478317173. View

3.
. Tamoxifen for early breast cancer. Cochrane Database Syst Rev. 2001; (1):CD000486. DOI: 10.1002/14651858.CD000486. View

4.
Mitchell G, Trott P, Morris L, Coleman N, Sauter E, Eeles R . Cellular characteristics of nipple aspiration fluid during the menstrual cycle in healthy premenopausal women. Cytopathology. 2001; 12(3):184-96. DOI: 10.1046/j.1365-2303.2001.00313.x. View

5.
Dooley W, Ljung B, Veronesi U, Cazzaniga M, Elledge R, OShaughnessy J . Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst. 2001; 93(21):1624-32. DOI: 10.1093/jnci/93.21.1624. View